News

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company" ...
Pharmabiz36m
Merck to initiate EXPrESSIVE phase 3 trials of MK-8527, an investigational once-monthly HIV prevention pill
Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...